• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

半胱氨酸蛋白酶组织蛋白酶在动脉粥样硬化和腹主动脉瘤中的作用

Cysteine Protease Cathepsins in Atherosclerosis and Abdominal Aortic Aneurysm.

作者信息

Sjöberg Sara, Shi Guo-Ping

机构信息

Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

出版信息

Clin Rev Bone Miner Metab. 2011 Jun 1;9(2):138-147. doi: 10.1007/s12018-011-9098-2. Epub 2011 Jun 18.

DOI:10.1007/s12018-011-9098-2
PMID:22505840
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3324310/
Abstract

Extracellular matrix remodeling is an important mechanism in the initiation and progression of cardiovascular diseases. Cysteine protease cathepsins are among the important proteases that affect major events in the pathogenesis of atherosclerosis and abdominal aortic aneurysm, including smooth muscle cell transmigration through elastic lamina, macrophage foam cell formation, vascular cell and macrophage apoptosis, and plaque rupture. These events have been studied in cathepsin deficiencies and cathepsin inhibitor deficiencies in mice and have provided invaluable insights regarding the roles of cathepsins in cardiovascular diseases. Pharmacological inhibitions for cathepsins are under evaluation for other human diseases and may be used as clinical treatments for cardiovascular diseases in the near future. This article reviews different mechanisms for cathepsins in atherosclerosis and abdominal aortic aneurysm that could be targeted by selective cathepsin inhibitors.

摘要

细胞外基质重塑是心血管疾病发生和发展的重要机制。半胱氨酸蛋白酶组织蛋白酶是影响动脉粥样硬化和腹主动脉瘤发病机制中主要事件的重要蛋白酶之一,这些事件包括平滑肌细胞穿过弹性膜迁移、巨噬细胞泡沫细胞形成、血管细胞和巨噬细胞凋亡以及斑块破裂。在小鼠的组织蛋白酶缺陷和组织蛋白酶抑制剂缺陷中对这些事件进行了研究,这些研究为组织蛋白酶在心血管疾病中的作用提供了宝贵的见解。组织蛋白酶的药理学抑制作用正在针对其他人类疾病进行评估,并且在不久的将来可能用作心血管疾病的临床治疗方法。本文综述了组织蛋白酶在动脉粥样硬化和腹主动脉瘤中的不同作用机制,这些机制可能成为选择性组织蛋白酶抑制剂的作用靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fce/3324310/408a4daa001a/nihms366164f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fce/3324310/408a4daa001a/nihms366164f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fce/3324310/408a4daa001a/nihms366164f1.jpg

相似文献

1
Cysteine Protease Cathepsins in Atherosclerosis and Abdominal Aortic Aneurysm.半胱氨酸蛋白酶组织蛋白酶在动脉粥样硬化和腹主动脉瘤中的作用
Clin Rev Bone Miner Metab. 2011 Jun 1;9(2):138-147. doi: 10.1007/s12018-011-9098-2. Epub 2011 Jun 18.
2
Do cathepsins play a role in abdominal aortic aneurysm pathogenesis?组织蛋白酶在腹主动脉瘤发病机制中起作用吗?
Ann N Y Acad Sci. 2006 Nov;1085:161-9. doi: 10.1196/annals.1383.028.
3
Cysteine protease cathepsins in atherosclerosis-based vascular disease and its complications.半胱氨酸蛋白酶组织蛋白酶在动脉粥样硬化性血管疾病及其并发症中的作用。
Hypertension. 2011 Dec;58(6):978-86. doi: 10.1161/HYPERTENSIONAHA.111.180935. Epub 2011 Oct 10.
4
Cysteinyl cathepsins and mast cell proteases in the pathogenesis and therapeutics of cardiovascular diseases.半胱氨酸蛋白酶和肥大细胞蛋白酶在心脑血管疾病发病机制和治疗中的作用。
Pharmacol Ther. 2011 Sep;131(3):338-50. doi: 10.1016/j.pharmthera.2011.04.010. Epub 2011 May 12.
5
Cathepsin cysteine proteases in cardiovascular disease.心血管疾病中的组织蛋白酶半胱氨酸蛋白酶
FASEB J. 2007 Oct;21(12):3029-41. doi: 10.1096/fj.06-7924com. Epub 2007 May 23.
6
Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases.半胱氨酸蛋白酶组织蛋白酶在动脉粥样硬化性心血管疾病中的作用。
J Atheroscler Thromb. 2018 Feb 1;25(2):111-123. doi: 10.5551/jat.RV17016. Epub 2017 Oct 5.
7
Cysteine protease cathepsins in cardiovascular disease: from basic research to clinical trials.半胱氨酸蛋白酶组织蛋白酶在心血管疾病中的作用:从基础研究到临床试验。
Nat Rev Cardiol. 2018 Jun;15(6):351-370. doi: 10.1038/s41569-018-0002-3.
8
Cystatin C and cathepsins in cardiovascular disease.心血管疾病中的胱抑素C和组织蛋白酶
Front Biosci. 2008 May 1;13:5780-6. doi: 10.2741/3115.
9
Unravelling the role of cathepsins in cardiovascular diseases.解析组织蛋白酶在心血管疾病中的作用。
Mol Biol Rep. 2024 Apr 26;51(1):579. doi: 10.1007/s11033-024-09518-1.
10
Cathepsin L expression and regulation in human abdominal aortic aneurysm, atherosclerosis, and vascular cells.组织蛋白酶L在人腹主动脉瘤、动脉粥样硬化及血管细胞中的表达与调控
Atherosclerosis. 2006 Feb;184(2):302-11. doi: 10.1016/j.atherosclerosis.2005.05.012. Epub 2005 Jun 27.

引用本文的文献

1
A composite docking approach for the identification and characterization of ectosteric inhibitors of cathepsin K.一种用于鉴定和表征组织蛋白酶K变构抑制剂的复合对接方法。
PLoS One. 2017 Oct 31;12(10):e0186869. doi: 10.1371/journal.pone.0186869. eCollection 2017.
2
Cysteine Protease Cathepsins in Atherosclerotic Cardiovascular Diseases.半胱氨酸蛋白酶组织蛋白酶在动脉粥样硬化性心血管疾病中的作用。
J Atheroscler Thromb. 2018 Feb 1;25(2):111-123. doi: 10.5551/jat.RV17016. Epub 2017 Oct 5.
3
The HIV Protease Inhibitor Saquinavir Inhibits HMGB1-Driven Inflammation by Targeting the Interaction of Cathepsin V with TLR4/MyD88.

本文引用的文献

1
Osteoporosis: now and the future.骨质疏松症:现在与未来。
Lancet. 2011 Apr 9;377(9773):1276-87. doi: 10.1016/S0140-6736(10)62349-5. Epub 2011 Mar 28.
2
Deficiency of antigen-presenting cell invariant chain reduces atherosclerosis in mice.抗原呈递细胞不变链缺陷可减少小鼠动脉粥样硬化。
Circulation. 2010 Aug 24;122(8):808-20. doi: 10.1161/CIRCULATIONAHA.109.891887. Epub 2010 Aug 9.
3
Cystatin C deficiency promotes inflammation in angiotensin II-induced abdominal aortic aneurisms in atherosclerotic mice.半胱氨酸蛋白酶抑制剂 C 缺乏促进动脉粥样硬化小鼠血管紧张素 II 诱导的腹主动脉瘤中的炎症反应。
艾滋病病毒蛋白酶抑制剂沙奎那韦通过靶向组织蛋白酶V与Toll样受体4/髓样分化因子88的相互作用来抑制高迁移率族蛋白B1驱动的炎症反应。
Mol Med. 2015 Dec;21(1):749-757. doi: 10.2119/molmed.2015.00197. Epub 2015 Sep 2.
4
Cathepsins: a new culprit behind abdominal aortic aneurysm.组织蛋白酶:腹主动脉瘤背后的新罪魁祸首。
Regen Med Res. 2013 Nov 1;1(1):5. doi: 10.1186/2050-490X-1-5. eCollection 2013 Dec.
5
Structural basis of collagen fiber degradation by cathepsin K.组织蛋白酶K降解胶原纤维的结构基础
Proc Natl Acad Sci U S A. 2014 Dec 9;111(49):17474-9. doi: 10.1073/pnas.1414126111. Epub 2014 Nov 24.
6
Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects.组织蛋白酶S抑制剂LY3000328在健康受试者中的药代动力学和药效学
Br J Clin Pharmacol. 2014 Dec;78(6):1334-42. doi: 10.1111/bcp.12470.
7
Effect of poloxamer 407 administration on the serum lipids profile, anxiety level and protease activity in the heart and liver of mice.泊洛沙姆407给药对小鼠血清脂质谱、焦虑水平及心脏和肝脏蛋白酶活性的影响。
Interdiscip Toxicol. 2013 Mar;6(1):18-25. doi: 10.2478/intox-2013-0004.
8
Pharmaceutical stabilization of mast cells attenuates experimental atherogenesis in low-density lipoprotein receptor-deficient mice.药物稳定肥大细胞可减轻载脂蛋白 E 基因缺陷小鼠的动脉粥样硬化形成。
Atherosclerosis. 2013 Aug;229(2):304-9. doi: 10.1016/j.atherosclerosis.2013.05.025. Epub 2013 Jun 7.
9
Proteolytic characteristics of cathepsin D related to the recognition and cleavage of its target proteins.组织蛋白酶 D 的蛋白水解特性与其靶蛋白的识别和切割有关。
PLoS One. 2013 Jun 20;8(6):e65733. doi: 10.1371/journal.pone.0065733. Print 2013.
Am J Pathol. 2010 Jul;177(1):456-63. doi: 10.2353/ajpath.2010.090381. Epub 2010 May 14.
4
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals.NLRP3 炎性小体对于动脉粥样硬化的形成是必需的,并且可以被胆固醇晶体激活。
Nature. 2010 Apr 29;464(7293):1357-61. doi: 10.1038/nature08938.
5
Pharmacological inhibition of cathepsin S decreases atherosclerotic lesions in Apoe-/- mice.组织蛋白酶 S 的药理学抑制可减少 Apoe-/- 小鼠的动脉粥样硬化病变。
J Cardiovasc Pharmacol. 2010 Jul;56(1):98-105. doi: 10.1097/FJC.0b013e3181e23e10.
6
Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?抗组织蛋白酶 K 药物的未来:骨骼疾病和动脉粥样硬化的双重治疗?
Future Med Chem. 2009 Apr;1(1):21-34. doi: 10.4155/fmc.09.4.
7
Odanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.odanacatib,一种用于治疗骨质疏松症及其他与过度骨重塑相关骨骼疾病的组织蛋白酶K抑制剂。
IDrugs. 2009 Dec;12(12):799-809.
8
Cathepsin K gene disruption does not affect murine aneurysm formation.组织蛋白酶 K 基因缺失不影响小鼠动脉瘤的形成。
Atherosclerosis. 2010 Mar;209(1):96-103. doi: 10.1016/j.atherosclerosis.2009.09.001. Epub 2009 Sep 6.
9
Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease.慢性肾病中弹性蛋白酶解组织蛋白酶S缺乏可消除动脉和主动脉瓣钙化。
Circulation. 2009 Apr 7;119(13):1785-94. doi: 10.1161/CIRCULATIONAHA.108.827972. Epub 2009 Mar 23.
10
Leukocyte cathepsin S is a potent regulator of both cell and matrix turnover in advanced atherosclerosis.白细胞组织蛋白酶S是晚期动脉粥样硬化中细胞和基质更新的有效调节因子。
Arterioscler Thromb Vasc Biol. 2009 Feb;29(2):188-94. doi: 10.1161/ATVBAHA.108.181578. Epub 2008 Dec 18.